 IRVINE, Calif.--BUSINESS WIRE--Axonics Modulation Technologies, Inc. NASDAQ: AXNX, a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation SNM devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval PMA supplement to the FDA for the purpose of gaining detachable extremity coil magnetic resonance imaging MRI conditional labeling for 1.5T and 3.0T MR scanners. The FDA previously approved 1.5T 